Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Imatinib | Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with an IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. Imatinib is an oral chemotherapy agent used to treat cancers. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Group: Pharmaceutical. CAS No. 152459-95-5. Pack Sizes: 10 g. Product ID: BBF-05855. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Imatinib-[d4] | Imatinib-[d4] is an isotopically labelled analogue of Imatinib. Imatinib is an inhibitor of multiple tyrosine kinases. It is a COVID-19-related research product. Group: Pharmaceutical. CAS No. 1134803-16-9. Pack Sizes: 5 mg. Product ID: BLP-005865. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib EP Impurity D | An impurity of Imatinib, a tyrosine kinase inhibitor used as a chemotherapy drug for the treatment of leukemia and other kinds of cancer. Group: Pharmaceutical. CAS No. 1821122-73-9. Pack Sizes: 100 mg. Product ID: B2694-473167. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib EP Impurity J | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. CAS No. 571186-91-9. Pack Sizes: 10 mg. Product ID: B2694-473158. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Guanidine Impurity | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. CAS No. 581076-65-5. Pack Sizes: 100 mg. Product ID: B2694-257315. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Impurities | Imatinib Impurities, comprised of various byproducts from imatinib synthesis, are critical in quality control for pharmaceutical research. These impurities help identify and quantify deviations in the production of imatinib, a drug primarily used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, ensuring its safety and effectiveness. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Impurity C | an impurity of Imatinib (Gleevec). Group: Pharmaceutical. CAS No. 938082-57-6. Pack Sizes: 10 mg. Product ID: B2694-473162. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Impurity E | an impurity of Imatinib (Gleevec). Group: Pharmaceutical. CAS No. 1365802-18-1. Pack Sizes: 10 mg. Product ID: B2694-473163. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Impurity M | An impurity of Imatinib, a tyrosine kinase inhibitor used as a chemotherapy drug for the treatment of leukemia and other kinds of cancer. Group: Pharmaceutical. CAS No. 1407229-73-5. Pack Sizes: 25 mg. Product ID: B2694-104820. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib mesylate | 100mg Pack Size. Group: Bioactive Small Molecules, Research Organics & Inorganics. Formula: C29H31N7O · CH4O3S. CAS No. 220127-57-1. Prepack ID : 60579435-100mg. Molecular Weight : 589.71. |  |
| Imatinib mesylate | Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Group: Pharmaceutical. CAS No. 220127-57-1. Pack Sizes: 10 g. Product ID: NP3279. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Related Substance B | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. CAS No. 571186-93-1. Pack Sizes: 5 mg. Product ID: B2694-473161. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Imatinib | A metabolite of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. CAS No. 404844-02-6. Pack Sizes: 10 mg. Product ID: B2694-473156. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Imatinib-[d8] | N-Desmethyl Imatinib-[d8] is a deuterated metabolite of gleevec, a tyrosine kinase inhibitor specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Group: Pharmaceutical. CAS No. 1185103-28-9. Pack Sizes: 5 mg. Product ID: BLP-009648. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Dasatinib | Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Group: Pharmaceutical. CAS No. 302962-49-8. Pack Sizes: 25 g. Product ID: NP3264. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| DCC-2618 | DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. Group: Pharmaceutical. CAS No. 1225278-16-9. Pack Sizes: 50 mg. Product ID: B0084-457687. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Icaritin | Icaritin is unable to promote proliferation, migration and tube-like structure formation by human umbilical vein endothelial cells (HUVECs) in vitro. Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 μM) and primary CML cells (IC50 was 13.4 μM for CML-CP and 18 μM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML) and Imatinib-resistant cells, and to induce apoptosis. Icaritin strongly inhibited the growth of breast cancer MDA-MB-453 and MCF7 cells. At concentrations of 2-3 μM, icaritin induced cell cycle arrest at the G(2)/M phase accompanied by a down-regulation of the expression levels of the G(2)/M regulatory proteins such as cyclinB, cdc2 and cdc25C. Icaritin at concentrations of 4-5 μM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression. In mouse leukemia model, Icaritin could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells as effective as Imatinib without suppression of bone marrow. Icaritin could up-regulate phospho-JNK or phospho-C-Jun and down-regulate phospho-ERK, phospho-P-38, Jak-2, phospho-Stat3 and phospho-Akt expression with dose- or ti | London |
| Radotinib | Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Check for active clinical trials or closed clinical trials using this agent. Group: Pharmaceutical. CAS No. 926037-48-1. Pack Sizes: 50 mg. Product ID: B0084-465339. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sunitinib malate | Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Uses: Angiogenesis inhibitors. Group: Pharmaceutical. CAS No. 341031-54-7. Pack Sizes: 1 g. Product ID: NP3249. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
